Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Bertoli

Showing results (31-40 of 96) with videos related to

Pageof 10
Sort By:
Leukemia Research|May 6, 2019
Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitorsLaetitia Largeaud, Emilie Bérard, Sarah Bertoli, et al.
Scientific Reports|March 6, 2026
Characteristics of patients diagnosed for acute myeloid leukemia before and during the 2020 COVID-19 pandemic: the DATAML population-based cohortSébastien Lamy, Raphaël Fenni, Suzanne Tavitian, et al.
Leukemia & Lymphoma|November 12, 2020
Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patientsChloé Medrano, Lucie Oberic, Florent Puisset, et al.
Leukemia & Lymphoma|October 1, 2019
Outcome of relapsed/refractory AML patients with IDH1<sup>R132</sup> mutations in real life before the era of IDH1 inhibitorsLaetitia Largeaud, Sarah Bertoli, Emilie Bérard, et al.
Leukemia & Lymphoma|February 6, 2020
More than ten percent of relapses occur after five years in AML patients with <i>NPM1</i> mutationSarah Bertoli, Suzanne Tavitian, Emilie Bérard, et al.
Blood Advances|September 6, 2023
Vitamin C and D supplementation in acute myeloid leukemiaPierre Luc Mouchel, Emilie Bérard, Suzanne Tavitian, et al.
Oncotarget|November 8, 2017
Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemiaPierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
American Journal of Hematology|September 12, 2025
Association Between Molecular Profile and Outcome After Intensive Chemotherapy in Patients > 60 Years With Secondary and/or Adverse Cytogenetics Acute Myeloid Leukemia-A FILO StudyCorentin Orvain, Anne Bouvier, Audrey Bidet, et al.
Cancers|May 10, 2020
CD34<sup>+</sup>CD38<sup>-</sup>CD123<sup>+</sup> Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating AgentsFrançois Vergez, Marie-Laure Nicolau-Travers, Sarah Bertoli, et al.
American Journal of Hematology|March 15, 2025
Venetoclax-Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC-DATAML-MSKCC Retrospective StudyCassandre Petit, Jules Higue, Ziyad Acheaibi, et al.
Pageof 10

Showing results (31-40 of 96) with videos related to

Sort By:
Pageof 10
Leukemia Research|May 6, 2019
Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitorsLaetitia Largeaud, Emilie Bérard, Sarah Bertoli, et al.
Scientific Reports|March 6, 2026
Characteristics of patients diagnosed for acute myeloid leukemia before and during the 2020 COVID-19 pandemic: the DATAML population-based cohortSébastien Lamy, Raphaël Fenni, Suzanne Tavitian, et al.
Leukemia & Lymphoma|November 12, 2020
Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patientsChloé Medrano, Lucie Oberic, Florent Puisset, et al.
Leukemia & Lymphoma|October 1, 2019
Outcome of relapsed/refractory AML patients with IDH1<sup>R132</sup> mutations in real life before the era of IDH1 inhibitorsLaetitia Largeaud, Sarah Bertoli, Emilie Bérard, et al.
Leukemia & Lymphoma|February 6, 2020
More than ten percent of relapses occur after five years in AML patients with <i>NPM1</i> mutationSarah Bertoli, Suzanne Tavitian, Emilie Bérard, et al.
Blood Advances|September 6, 2023
Vitamin C and D supplementation in acute myeloid leukemiaPierre Luc Mouchel, Emilie Bérard, Suzanne Tavitian, et al.
Oncotarget|November 8, 2017
Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemiaPierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
American Journal of Hematology|September 12, 2025
Association Between Molecular Profile and Outcome After Intensive Chemotherapy in Patients > 60 Years With Secondary and/or Adverse Cytogenetics Acute Myeloid Leukemia-A FILO StudyCorentin Orvain, Anne Bouvier, Audrey Bidet, et al.
Cancers|May 10, 2020
CD34<sup>+</sup>CD38<sup>-</sup>CD123<sup>+</sup> Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating AgentsFrançois Vergez, Marie-Laure Nicolau-Travers, Sarah Bertoli, et al.
American Journal of Hematology|March 15, 2025
Venetoclax-Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC-DATAML-MSKCC Retrospective StudyCassandre Petit, Jules Higue, Ziyad Acheaibi, et al.
Pageof 10